Helen I. Torley
2015
In 2015, Helen I. Torley earned a total compensation of $4.6M as President and Chief Executive Officer at Halozyme Therapeutics, a 56% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $616,356 |
|---|---|
| Option Awards | $1,633,600 |
| Salary | $624,000 |
| Stock Awards | $1,733,750 |
| Other | $9,081 |
| Total | $4,616,787 |
Torley received $1.7M in stock awards, accounting for 38% of the total pay in 2015.
Torley also received $616.4K in non-equity incentive plan, $1.6M in option awards, $624K in salary and $9.1K in other compensation.
Rankings
In 2015, Helen I. Torley's compensation ranked 1,786th out of 13,638 executives tracked by ExecPay. In other words, Torley earned more than 86.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,786 out of 13,638 | 87th |
Division Manufacturing | 646 out of 5,187 | 88th |
Major group Chemicals And Allied Products | 238 out of 1,857 | 87th |
Industry group Drugs | 184 out of 1,531 | 88th |
Industry Biological Products, Except Diagnostic Substances | 30 out of 260 | 89th |
Source: SEC filing on March 24, 2017.
Torley's colleagues
We found four more compensation records of executives who worked with Helen I. Torley at Halozyme Therapeutics in 2015.
News
Halozyme Therapeutics CEO Helen Torley's 2021 pay rises 14% to $7.5M
March 25, 2022
Halozyme Therapeutics CEO Helen Torley's 2020 pay rises 11% to $6.5M
March 26, 2021
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019